A trial flop for Massachusetts, USA-based EyePoint Pharmaceuticals (Nasdaq: EYPT) has triggered a sell-off from investors, with the price of a share dropping by around half.
EyePoint, a specialist in serious retinal diseases, announced top-line results from its Phase II PAVIA trial evaluating Duravyu (vorolanib), previously known as EYP-1901.
The intravitreal insert is being developed for people with non-proliferative diabetic retinopathy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze